Search

Your search keyword '"Strauss, Sandra"' showing total 121 results
Start Over Author "Strauss, Sandra" Search Limiters Peer Reviewed
121 results on '"Strauss, Sandra"'

1. Co-targeting SOS1 enhances the antitumor effects of KRASG12C inhibitors by addressing intrinsic and acquired resistance

Author

Thatikonda, Venu, Lyu, Hengyu, Jurado, Sabine, Kostyrko, Kaja, Bristow, Christopher A., Albrecht, Christoph, Alpar, Donat, Arnhof, Heribert, Bergner, Oliver, Bosch, Karin, Feng, Ningping, Gao, Sisi, Gerlach, Daniel, Gmachl, Michael, Hinkel, Melanie, Lieb, Simone, Jeschko, Astrid, Machado, Annette A., Madensky, Thomas, Marszalek, Ethan D., Mahendra, Mikhila, Melo-Zainzinger, Gabriella, Molkentine, Jessica M., Jaeger, Philipp A., Peng, David H., Schenk, Robyn L., Sorokin, Alexey, Strauss, Sandra, Trapani, Francesca, Kopetz, Scott, Vellano, Christopher P., Petronczki, Mark, Kraut, Norbert, Heffernan, Timothy P., Marszalek, Joseph R., Pearson, Mark, Waizenegger, Irene C., and Hofmann, Marco H.

Published
2024
Full Text
View/download PDF

2. Impact of age on safety of Busulfan-Melphalan followed by autologous hematopoietic stem-cell transplantation versus standard chemotherapy in the patients of the EURO-E.W.I.N.G. 99 and Ewing 2008 clinical trials

Author

Choderlos de Laclos, Xavier, Risbourg, Séverine, Brennan, Bernadette, Bertucci, François, Gaspar, Nathalie, Gelderblom, Hans, Hawkins, Douglas S., Janeway, Katherine, Juergens, Heribert, Kasper, Bernd, Krailo, Mark D., Cécile Le Deley, Marie, Marec-Bérard, Perrine, McCabe, Martin G., Metzler, Markus, Ranft, Andreas, Strauss, Sandra, Tabone, Marie-Dominique, Windsor, Rachael, Dirksen, Uta, and Gandemer, Virginie

Published
2024
Full Text
View/download PDF

5. Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial

Author

D'Angelo, Sandra P, Araujo, Dejka M, Abdul Razak, Albiruni R, Agulnik, Mark, Attia, Steven, Blay, Jean-Yves, Carrasco Garcia, Irene, Charlson, John A, Choy, Edwin, Demetri, George D, Druta, Mihaela, Forcade, Edouard, Ganjoo, Kristen N, Glod, John, Keedy, Vicki L, Le Cesne, Axel, Liebner, David A, Moreno, Victor, Pollack, Seth M, Schuetze, Scott M, Schwartz, Gary K, Strauss, Sandra J, Tap, William D, Thistlethwaite, Fiona, Valverde Morales, Claudia Maria, Wagner, Michael J, Wilky, Breelyn A, McAlpine, Cheryl, Hudson, Laura, Navenot, Jean-Marc, Wang, Tianjiao, Bai, Jane, Rafail, Stavros, Wang, Ruoxi, Sun, Amy, Fernandes, Lilliam, Van Winkle, Erin, Elefant, Erica, Lunt, Colin, Norry, Elliot, Williams, Dennis, Biswas, Swethajit, and Van Tine, Brian A

Published
2024
Full Text
View/download PDF

6. European standard clinical practice recommendations for children and adolescents with primary and recurrent osteosarcoma

Author

van Ewijk, Roelof, Herold, Nikolas, Baecklund, Fredrik, Baumhoer, Daniel, Boye, Kjetil, Gaspar, Nathalie, Harrabi, Semi B., Haveman, Lianne M., Hecker-Nolting, Stefanie, Hiemcke-Jiwa, Laura, Martin, Valentine, Fernández, Cristina Mata, Palmerini, Emanuela, van de Sande, Michiel A.J., Strauss, Sandra J., Bielack, Stefan S., and Kager, Leo

Published
2023
Full Text
View/download PDF

9. Aberrant paracrine signalling for bone remodelling underlies the mutant histone-driven giant cell tumour of bone

Author

Cottone, Lucia, Ligammari, Lorena, Lee, Hang-Mao, Knowles, Helen J., Henderson, Stephen, Bianco, Sara, Davies, Christopher, Strauss, Sandra, Amary, Fernanda, Leite, Ana Paula, Tirabosco, Roberto, Haendler, Kristian, Schultze, Joachim L., Herrero, Javier, O’Donnell, Paul, Grigoriadis, Agamemnon E., Salomoni, Paolo, and Flanagan, Adrienne M.

Published
2022
Full Text
View/download PDF

10. Retrospective observational studies in ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society (CTOS) community of experts on the minimum requirements for the evaluation of activity of systemic treatments

Author

Stacchiotti, Silvia, Maria Frezza, Anna, Demetri, George D., Blay, Jean-Yves, Bajpai, Jyoti, Baldi, Giacomo G., Baldini, Elizabeth H., Benjamin, Robert S., Bonvalot, Sylvie, Bovée, Judith V.M.G., Callegaro, Dario, Casali, Paolo G., D'Angelo, Sandra P., Davis, Elizabeth J., Dei Tos, Angelo P., Demicco, Elizabeth G., Desai, Jayesh, Dileo, Palma, Eriksson, Mikael, Gelderblom, Hans, George, Suzanne, Gladdy, Rebecca A., Gounder, Mrinal M., Gupta, Abha A., Haas, Rick, Hayes, Andrea, Hohenberger, Peter, Jones, Kevin B., Jones, Robin L., Kasper, Bernd, Kawai, Akira, Kirsch, David G., Kleinerman, Eugenie S., Le Cesne, Axel, Maestro, Roberta, Martin Broto, Javier, Maki, Robert G., Miah, Aisha B., Palmerini, Emanuela, Patel, Shreaskumar R., Raut, Chandrajit P., Razak, Albiruni R.A., Reed, Damon R., Rutkowski, Piotr, Sanfilippo, Roberta G., Sbaraglia, Marta, Schaefer, Inga-Marie, Strauss, Dirk C., Strauss, Sandra J., Tap, William D., Thomas, David M., Trama, Annalisa, Trent, Jonathan C., van der Graaf, Winette T.A., van Houdt, Winan J., von Mehren, Margaret, Wilky, Breelyn A., Fletcher, Christopher D.M., Gronchi, Alessandro, Miceli, Rosalba, and Wagner, Andrew J.

Published
2022
Full Text
View/download PDF

12. Paediatric Strategy Forum for medicinal product development of multi-targeted kinase inhibitors in bone sarcomas: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration

Author

Pearson, Andrew DJ., Gaspar, Nathalie, Janeway, Katherine, Campbell-Hewson, Quentin, Lawlor, Elizabeth R., Copland, Chris, Karres, Dominik, Norga, Koen, Benzaghou, Fawzi, Weiner, Susan, Weigel, Brenda, Weiss, Aaron R., Strauss, Sandra J., Smith, Malcolm, Setty, Bhuvana A., Seibel, Nita, Scobie, Nicole, Pappo, Alberto, Okpara, Chinyere E., Nysom, Karsten, McDonough, Joe, Marshall, Lynley V., Ludwinski, Donna, Ligas, Franca, Lesa, Giovanni, Knudsen, Steen, Kauh, John, Hsieh, Antony, Heenen, Delphine, Hawkins, Douglas S., Graham, Ann, Garmey, Edward, DuBois, Steven G., Fox, Elizabeth, Donoghue, Martha, de Rojas, Teresa, Chung, John, Casanova, Michela, Brennan, Bernadette, Bishop, Michael, Buenger, Vickie, Reaman, Gregory, and Vassal, Gilles

Published
2022
Full Text
View/download PDF

14. Lenvatinib Plus Ifosfamide and Etoposide in Children and Young Adults With Relapsed Osteosarcoma: A Phase 2 Randomized Clinical Trial.

Author

Gaspar, Nathalie, Hung, Giun-Yi, Strauss, Sandra J., Campbell-Hewson, Quentin, Dela Cruz, Filemon S., Glade Bender, Julia L., Koh, Kyung-Nam, Whittle, Sarah B., Chan, Godfrey Chi-Fung, Gerber, Nicolas U., Palmu, Sauli, Morgenstern, Daniel A., Longhi, Alessandra, Baecklund, Fredrik, Lee, Jun Ah, Locatelli, Franco, Márquez Vega, Catalina, Janeway, Katherine A., McCowage, Geoffrey, and McCabe, Martin G.

Published
2024
Full Text
View/download PDF

15. Outcomes from a mechanistic biomarker multi-arm and randomised study of liposomal MTP-PE (Mifamurtide) in metastatic and/or recurrent osteosarcoma (EuroSarc-Memos trial)

Author

Barnes, David J., Dutton, Peter, Bruland, Øyvind, Gelderblom, Hans, Faleti, Ade, Bühnemann, Claudia, van Maldegem, Annemiek, Johnson, Hannah, Poulton, Lisa, Love, Sharon, Tiemeier, Gesa, van Beelen, Els, Herbschleb, Karin, Haddon, Caroline, Billingham, Lucinda, Bradley, Kevin, Ferrari, Stefano, Palmerini, Emanuela, Picci, Piero, Dirksen, Uta, Strauss, Sandra J., Hogendoorn, Pancras C. W., Buddingh, Emmeline, Blay, Jean-Yves, Cleton-Jansen, Anne Marie, and Hassan, Andrew Bassim

Published
2022
Full Text
View/download PDF

16. Long-term efficacy update of crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumour from EORTC trial 90101 CREATE

Author

Schöffski, Patrick, Kubickova, Michaela, Wozniak, Agnieszka, Blay, Jean-Yves, Strauss, Sandra J., Stacchiotti, Silvia, Switaj, Tomasz, Bücklein, Veit, Leahy, Michael G., Italiano, Antoine, Isambert, Nicolas, Debiec-Rychter, Maria, Sciot, Raf, Lee, Che-Jui, Speetjens, Frank M., Nzokirantevye, Axelle, Neven, Anouk, and Kasper, Bernd

Published
2021
Full Text
View/download PDF

17. Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050): a multicentre, open-label, multicohort, phase 1/2 study

Author

Gaspar, Nathalie, Venkatramani, Rajkumar, Hecker-Nolting, Stefanie, Melcon, Soledad Gallego, Locatelli, Franco, Bautista, Francisco, Longhi, Alessandra, Lervat, Cyril, Entz-Werle, Natacha, Casanova, Michela, Aerts, Isabelle, Strauss, Sandra J, Thebaud, Estelle, Morland, Bruce, Nieto, Adela Cañete, Marec-Berard, Perrine, Gambart, Marion, Rossig, Claudia, Okpara, Chinyere E, He, Cixin, Dutta, Lea, and Campbell-Hewson, Quentin

Published
2021
Full Text
View/download PDF

18. Multimodal analysis of cell-free DNA whole-genome sequencing for pediatric cancers with low mutational burden

Author

Peneder, Peter, Stütz, Adrian M., Surdez, Didier, Krumbholz, Manuela, Semper, Sabine, Chicard, Mathieu, Sheffield, Nathan C., Pierron, Gaelle, Lapouble, Eve, Tötzl, Marcus, Ergüner, Bekir, Barreca, Daniele, Rendeiro, André F., Agaimy, Abbas, Boztug, Heidrun, Engstler, Gernot, Dworzak, Michael, Bernkopf, Marie, Taschner-Mandl, Sabine, Ambros, Inge M., Myklebost, Ola, Marec-Bérard, Perrine, Burchill, Susan Ann, Brennan, Bernadette, Strauss, Sandra J., Whelan, Jeremy, Schleiermacher, Gudrun, Schaefer, Christiane, Dirksen, Uta, Hutter, Caroline, Boye, Kjetil, Ambros, Peter F., Delattre, Olivier, Metzler, Markus, Bock, Christoph, and Tomazou, Eleni M.

Published
2021
Full Text
View/download PDF

20. Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort

Author

Smeland, Sigbjørn, Bielack, Stefan S., Whelan, Jeremy, Bernstein, Mark, Hogendoorn, Pancras, Krailo, Mark D., Gorlick, Richard, Janeway, Katherine A., Ingleby, Fiona C., Anninga, Jakob, Antal, Imre, Arndt, Carola, Brown, Ken L.B., Butterfass-Bahloul, Trude, Calaminus, Gabriele, Capra, Michael, Dhooge, Catharina, Eriksson, Mikael, Flanagan, Adrienne M., Friedel, Godehard, Gebhardt, Mark C., Gelderblom, Hans, Goldsby, Robert, Grier, Holcombe E., Grimer, Robert, Hawkins, Douglas S., Hecker-Nolting, Stefanie, Sundby Hall, Kirsten, Isakoff, Michael S., Jovic, Gordana, Kühne, Thomas, Kager, Leo, von Kalle, Thekla, Kabickova, Edita, Lang, Susanna, Lau, Ching C., Leavey, Patrick J., Lessnick, Stephen L., Mascarenhas, Leo, Mayer-Steinacker, Regine, Meyers, Paul A., Nagarajan, Raj, Randall, R.Lor, Reichardt, Peter, Renard, Marleen, Rechnitzer, Catherine, Schwartz, Cindy L., Strauss, Sandra, Teot, Lisa, Timmermann, Beate, Sydes, Matthew R., and Marina, Neyssa

Published
2019
Full Text
View/download PDF

21. A Prospective Observational Cohort Study for Newly Diagnosed Osteosarcoma Patients in the UK: ICONIC Study Initial Results.

Author

Childs, Alexa, Gerrand, Craig, Brennan, Bernadette, Young, Robin, Rankin, Kenneth S., Parry, Michael, Stevenson, Jonathan, Flanagan, Adrienne M., Taylor, Rachel M., Fern, Lorna, Heymann, Dominique, Vance, Filipa, Sherriff, Jenny, Singh, Saurabh, Begum, Rubina, Forsyth, Sharon L., Reczko, Krystyna, Sparksman, Kate, Wilson, William, and Strauss, Sandra J.

Subjects
OSTEOSARCOMA, RESEARCH funding, HUMAN beings, SCIENTIFIC observation, CANCER patients, TUMOR markers, LONGITUDINAL method, QUALITY of life, HEALTH outcome assessment, COLLECTION & preservation of biological specimens
Abstract

Simple Summary: Treatment for osteosarcoma (OS) has remained largely unchanged over the past 25 years. This is due in part to the low incidence of the disease, which makes the design of and recruitment to clinical trials challenging. The aim of our ongoing study is to establish a platform for the recruitment of newly diagnosed OS patients across the UK, with corresponding collection of clinical and patient-reported outcome (PRO) data, as well as biospecimen sample collection. In Stage 1 of the study, we established the feasibility of patient recruitment and patient data and sample collection. In Stage 2, biological and clinical data will be correlated with outcomes to develop prognostic biomarkers and inform the development of future clinical trials. There has been little change to the standard treatment for osteosarcoma (OS) over the last 25 years and there is an unmet need to identify new biomarkers and novel therapeutic approaches if outcomes are to improve. Furthermore, there is limited evidence on the impact of OS treatment on patient-reported outcomes (PROs). ICONIC (Improving Outcomes through Collaboration in Osteosarcoma; NCT04132895) is a prospective observational cohort study recruiting newly diagnosed OS patients across the United Kingdom (UK) with matched longitudinal collection of clinical, biological, and PRO data. During Stage 1, which assessed the feasibility of recruitment and data collection, 102 patients were recruited at 22 sites with representation from patient groups frequently excluded in OS studies, including patients over 50 years and those with less common primary sites. The feasibility of collecting clinical and biological samples, in addition to PRO data, has been established and there is ongoing analysis of these data as part of Stage 2. ICONIC will provide a unique, prospective cohort of newly diagnosed OS patients representative of the UK patient population, with fully annotated clinical outcomes linked to molecularly characterised biospecimens, allowing for comprehensive analyses to better understand biology and develop new biomarkers and novel therapeutic approaches. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

22. Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial

Author

Schöffski, Patrick, Sufliarsky, Jozef, Gelderblom, Hans, Blay, Jean-Yves, Strauss, Sandra J, Stacchiotti, Silvia, Rutkowski, Piotr, Lindner, Lars H, Leahy, Michael G, Italiano, Antoine, Isambert, Nicolas, Debiec-Rychter, Maria, Sciot, Raf, Van Cann, Thomas, Marréaud, Sandrine, Nzokirantevye, Axelle, Collette, Sandra, and Wozniak, Agnieszka

Published
2018
Full Text
View/download PDF

23. The tyrosine kinase inhibitor crizotinib does not have clinically meaningful activity in heavily pre-treated patients with advanced alveolar rhabdomyosarcoma with FOXO rearrangement: European Organisation for Research and Treatment of Cancer phase 2 trial 90101 ‘CREATE’

Author

Schöffski, Patrick, Wozniak, Agnieszka, Leahy, Michael G., Aamdal, Steinar, Rutkowski, Piotr, Bauer, Sebastian, Richter, Stephan, Grünwald, Viktor, Debiec-Rychter, Maria, Sciot, Raf, Geoerger, Birgit, Marréaud, Sandrine, Collette, Sandra, Nzokirantevye, Axelle, and Strauss, Sandra J.

Published
2018
Full Text
View/download PDF

24. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial

Author

Seddon, Beatrice, Strauss, Sandra J, Whelan, Jeremy, Leahy, Michael, Woll, Penella J, Cowie, Fiona, Rothermundt, Christian, Wood, Zoe, Benson, Charlotte, Ali, Nasim, Marples, Maria, Veal, Gareth J, Jamieson, David, Küver, Katja, Tirabosco, Roberto, Forsyth, Sharon, Nash, Stephen, Dehbi, Hakim-Moulay, and Beare, Sandy

Published
2017
Full Text
View/download PDF

26. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial

Author

Marina, Neyssa M, Smeland, Sigbjørn, Bielack, Stefan S, Bernstein, Mark, Jovic, Gordana, Krailo, Mark D, Hook, Jane M, Arndt, Carola, van den Berg, Henk, Brennan, Bernadette, Brichard, Bénédicte, Brown, Ken L B, Butterfass-Bahloul, Trude, Calaminus, Gabriele, Daldrup-Link, Heike E, Eriksson, Mikael, Gebhardt, Mark C, Gelderblom, Hans, Gerss, Joachim, Goldsby, Robert, Goorin, Allen, Gorlick, Richard, Grier, Holcombe E, Hale, Juliet P, Hall, Kirsten Sundby, Hardes, Jendrik, Hawkins, Douglas S, Helmke, Knut, Hogendoorn, Pancras C W, Isakoff, Michael S, Janeway, Katherine A, Jürgens, Heribert, Kager, Leo, Kühne, Thomas, Lau, Ching C, Leavey, Patrick J, Lessnick, Stephen L, Mascarenhas, Leo, Meyers, Paul A, Mottl, Hubert, Nathrath, Michaela, Papai, Zsuzsanna, Randall, R Lor, Reichardt, Peter, Renard, Marleen, Safwat, Akmal Ahmed, Schwartz, Cindy L, Stevens, Michael C G, Strauss, Sandra J, Teot, Lisa, Werner, Mathias, Sydes, Matthew R, and Whelan, Jeremy S

Published
2016
Full Text
View/download PDF

27. Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines

Author

Campbell, James, Ryan, Colm J., Brough, Rachel, Bajrami, Ilirjana, Pemberton, Helen N., Chong, Irene Y., Costa-Cabral, Sara, Frankum, Jessica, Gulati, Aditi, Holme, Harriet, Miller, Rowan, Postel-Vinay, Sophie, Rafiq, Rumana, Wei, Wenbin, Williamson, Chris T., Quigley, David A., Tym, Joe, Al-Lazikani, Bissan, Fenton, Timothy, Natrajan, Rachael, Strauss, Sandra J., Ashworth, Alan, and Lord, Christopher J.

Published
2016
Full Text
View/download PDF

28. International randomised controlled trial for the treatment of newly diagnosed EWING sarcoma family of tumours – EURO EWING 2012 Protocol

Author

Anderton, Jennifer, Moroz, Veronica, Marec-Bérard, Perrine, Gaspar, Nathalie, Laurence, Valerie, Martín-Broto, Javier, Sastre, Ana, Gelderblom, Hans, Owens, Cormac, Kaiser, Sophie, Fernández-Pinto, Melissa, Fenwick, Nicola, Evans, Abigail, Strauss, Sandra, Whelan, Jeremy, Wheatley, Keith, and Brennan, Bernadette

Published
2020
Full Text
View/download PDF

29. Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness

Author

Holme, Harriett, Gulati, Aditi, Brough, Rachel, Fleuren, Emmy D. G., Bajrami, Ilirjana, Campbell, James, Chong, Irene Y., Costa-Cabral, Sara, Elliott, Richard, Fenton, Tim, Frankum, Jessica, Jones, Samuel E., Menon, Malini, Miller, Rowan, Pemberton, Helen N., Postel-Vinay, Sophie, Rafiq, Rumana, Selfe, Joanna L., von Kriegsheim, Alex, Munoz, Amaya Garcia, Rodriguez, Javier, Shipley, Janet, van der Graaf, Winette T. A., Williamson, Chris T., Ryan, Colm J., Pettitt, Stephen, Ashworth, Alan, Strauss, Sandra J., and Lord, Christopher J.

Published
2018
Full Text
View/download PDF

30. Incidence and survival of soft tissue sarcoma in England between 2013 and 2017, an analysis from the National Cancer Registration and Analysis Service.

Author

Bacon, Andrew, Wong, Kwok, Fernando, Malee S., Rous, Brian, Hill, Roger J. W., Collins, Shane D., Broggio, John, and Strauss, Sandra J.

Subjects
SARCOMA, LIPOSARCOMA, TISSUE viability, GASTROINTESTINAL stromal tumors, PROPORTIONAL hazards models, NOSOLOGY
Abstract

There is a paucity of population‐based data detailing the incidence and survival of patients with soft tissue sarcoma (STS), in part due to the heterogeneity of disease and changes to classification. Here, the incidence and survival of all STS subtypes registered in England between 2013 and 2017 were analysed using cancer registry data held by the National Cancer Registration and Analysis Service. Age‐standardised incidence rates were calculated per 1 000 000 using the 2013 European Standard Population. Net survival was computed using Brenner's alternative method, with the Ederer II estimator. Age‐specific overall survival was assessed using Kaplan‐Meier. The influence of age, sex, socioeconomic deprivation and diagnostic routes on survival was assessed using Cox proportional hazards modelling. In total, 19 717 patients were diagnosed with STS, an average of 3943 patients per year and representing approximately 0.8% of malignancies. The most common histological diagnoses were Gastrointestinal Stromal Tumours (GIST), leiomyosarcoma and undifferentiated sarcoma, accounting for 20.2%, 13.3% and 12.7% of all sarcomas, respectively. Five‐year net survival for all malignant STS was 65.0%; and was lowest for patients with vascular tumours at 39%. Patients from most deprived cohorts had 23% greater chance of dying within 5 years than patients in least deprived areas. This population‐based study has allowed us for the first time to define the incidence and survival rates of prevalent STS subtypes in England such as GIST, liposarcoma and leiomyosarcoma, as well as rare entities and groups with inferior outcome. This data is invaluable for service provision, benchmarking and addressing inequality. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

37. Risk factors for colonization with extended-spectrum [beta]-lactamase-producing bacteria and intensive care unit admission

Author

Harris, Anthony D., McGregor, Jessina C., Johnson, Judith A., Strauss, Sandra M., Moore, Anita C., Standiford, Harold C., Hebden, Joan N., and Morris, J. Glenn, Jr.

Subjects
Beta lactamases -- Chemical properties, Drug resistance in microorganisms -- Observations, Bacterial infections -- Risk factors
Abstract

Extended-spectrum [beta]-lactamase (ESBL)-producing bacteria are emerging pathogens. To analyze risk factors for colonization with ESBL-producing bacteria at intensive care unit (ICU) admission, we conducted a prospective study of a 3.5-year [...]

Published
2007

38. Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci co-colonization (1)

Author

Furuno, Jon P., Perencevich, Eli N., Johnson, Judith A., Wright, Marc-Oliver, McGregor, Jessina C., Morris, J. Glenn, Jr., Strauss, Sandra M., Roghman, Mary-Claire, Nemoy, Lucia L., Standiford, Harold C., Hebden, Joan N., and Harris, Anthony D.

Subjects
University of Maryland, Baltimore. Medical Center -- Research, Vancomycin -- Research, Staphylococcus aureus -- Research
Abstract

We assessed the prevalence, risk factors, and clinical outcomes of patients co-colonized with vancomycin-resistant enterococci (VRE) and methicillin-resistant Staphylococcus aureus (MRSA) upon admission to the medical and surgical intensive care [...]

Published
2005

39. ERBB4 confers metastatic capacity in Ewing sarcoma

Author

Mendoza-Naranjo, Ariadna, El-Naggar, Amal, Wai, Daniel H., Mistry, Priti, Lazic, Nikola, Ayala, Fernanda Rocha Rojas, da Cunha, Isabela Werneck, Rodriguez-Viciana, Pablo, Cheng, Hongwei, Fregnani, Jose H. Tavares Guerreiro, Reynolds, Patrick, Arceci, Robert J., Nicholson, Andrew, Triche, Timothy J., Soares, Fernando A., Flanagan, Adrienne M., Wang, Yuzhuo Z., Strauss, Sandra J., and Sorensen, Poul H.

Published
2013
Full Text
View/download PDF

40. Improving head and neck sarcoma care: The impact of a specialized multidisciplinary team approach on diagnosis and patient outcomes.

Author

Tatsis, Dimitris, Sinha, Deepti, Le Grange, Franel, Jay, Amrita, Salli, Malla, Sadeghian, Golnaz, Morley, Simon, Wan, Simon, Karavasilis, Vasilios, Windsor, Rachael, Strauss, Sandra J., and Kalavrezos, Nicholas

Subjects
OSTEOSARCOMA, PROTON therapy, CANCER treatment, SARCOMA, OVERALL survival
Abstract

Globally, head & neck sarcoma care pathways remain unclear. In 2018, the London Sarcoma Service (LSS) set up a dedicated head and neck sarcoma (HNS) multidisciplinary team (MDT) with a clear objective to provide formal access to super-specialist expertise in diagnosis, treatment planning and management of HNS. The aim of the study is to provide first results of a dedicated HNS MDT. All patients discussed between 2018 and 2022, in HNS MDT, with a new histologically confirmed HNS diagnosis were included in the study. Demographics, anatomic site, morphology, MDT recommendation, treatment details and outcomes were obtained from electronic patient records. A total of 337 patients were discussed in the HNS MDT of which 178 patients were included in the study, with a median age of 53 years(range 2–94); 67 % were soft tissue sarcomas(STS) and 33 % were bone sarcomas(BS), of which 43 % and 71 % were high grade, respectively. 55 % BS and 39 % STS underwent surgery. 9 % of BS and 7 % of STS received adjuvant Proton Beam therapy. With a median follow-up of 2.16 years, recurrence was observed in 12 %, distant metastasis in 6 % of patients and overall survival was 72 %. The HNS MDT provides expertise on diagnosis and multi-modality management of HNS. STS are more likely to be misdiagnosed. Atypical imaging characteristics should trigger a specialist referral. Adequate surgery at first presentation remains the mainstay of treatment and the strongest prognosticator of overall survival. Formation of an expert working group specific to HNS must work towards streamlining sarcoma care. • Transformative Impact: Specialized MDT enhances Head and Neck Sarcoma Care • Optimizing Outcomes: Insights into Delays, Diagnostics, and Treatment Strategies • Integrated Approach: A Diagnostic Algorithm for Improved Patient Survival [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

47. SARC025 arms 1 and 2: A phase 1 study of the poly(ADP‐ribose) polymerase inhibitor niraparib with temozolomide or irinotecan in patients with advanced Ewing sarcoma.

Author

Chugh, Rashmi, Ballman, Karla V., Helman, Lee J., Patel, Shreyaskumar, Whelan, Jeremy S., Widemann, Brigitte, Lu, Yao, Hawkins, Douglas S., Mascarenhas, Leo, Glod, John W., Ji, Jiuping, Zhang, Yiping, Reinke, Denise, and Strauss, Sandra J.

Subjects
EWING'S sarcoma, ADENOSINE diphosphate ribose, POLY ADP ribose, IRINOTECAN, TEMOZOLOMIDE, ALANINE aminotransferase
Abstract

Background: In preclinical Ewing sarcoma (ES) models, poly(adenosine diphosphate ribose) polymerase (PARP) inhibitors were identified as a potential therapeutic strategy with synergy in combination with cytotoxic agents. This study evaluated the safety and dosing of the PARP1/2 inhibitor niraparib (NIR) with temozolomide (TMZ; arm 1) or irinotecan (IRN; arm 2) in patients with pretreated ES. Methods: Eligible patients in arm 1 received continuous NIR daily and escalating TMZ (days 2‐6 [D2‐6]) in cohort A. Subsequent patients received intermittent NIR dosing (cohort B), with TMZ re‐escalation in cohort C. In arm 2, patients were assigned to NIR (days 1‐7 [D1‐7]) and escalating doses of IRN (D2‐6). Results: From July 2014 to May 2018, 29 eligible patients (23 males and 6 females) were enrolled in arms 1 and 2, which had 7 dose levels combined. Five patients experienced at least 1 dose‐limiting toxicity (DLT) in arm 1 (grade 4 [G4] neutropenia for >7 days or G4 thrombocytopenia), and 3 patients experienced at least 1 DLT in arm 2 (grade 3 [G3] colitis, G3 anorexia, or G3 alanine aminotransferase elevation). The maximum tolerated dose was NIR at 200 mg every day on D1‐7 plus TMZ at 30 mg/m2 every day on D2‐6 (arm 1) or NIR at 100 mg every day on D1‐7 plus IRN at 20 mg/m2 every day on D2‐6 (arm 2). One confirmed partial response was observed in arm 2; the median progression‐free survival was 9.0 weeks (95% CI, 7.0‐10.1 weeks) and 16.3 weeks (95% CI, 5.1‐69.7 weeks) in arms 1 and 2, respectively. The median decrease in tumor poly(ADP‐ribose) activity was 89% (range, 83%‐98%). Conclusions: The combination of NIR and TMZ or IRN was tolerable, but at lower doses in comparison with conventional cytotoxic combinations. A triple‐combination study of NIR, IRN, and TMZ has commenced. Preclinical evaluations have identified the EWS‐FLI1 translocation, pathognomonic of Ewing sarcoma, as a predictive factor of response to poly(adenosine diphosphate ribose) polymerase (PARP) inhibitors with synergistic cell death in vivo with DNA damaging agents. This phase 1 study examines the dosing and safety of a combination of the PARP inhibitor niraparib with temozolomide or irinotecan. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

49. Sarcoma and the 100,000 Genomes Project: our experience and changes to practice.

Author

Prendergast, Sophie C, Strobl, Anna‐Christina, Cross, William, Pillay, Nischalan, Strauss, Sandra J, Ye, Hongtao, Lindsay, Daniel, Tirabosco, Roberto, Chalker, Jane, Mahamdallie, Shazia S, Sosinsky, Alona, Flanagan, Adrienne M, and Amary, Fernanda

Subjects
SARCOMA, EXPERIMENTAL design, CORE needle biopsy, GENOMES, GENE amplification, NUCLEOTIDE sequencing
Abstract

The largest whole genome sequencing (WGS) endeavour involving cancer and rare diseases was initiated in the UK in 2015 and ran for 5 years. Despite its rarity, sarcoma ranked third overall among the number of patients' samples sent for sequencing. Herein, we recount the lessons learned by a specialist sarcoma centre that recruited close to 1000 patients to the project, so that we and others may learn from our experience. WGS data was generated from 597 patients, but samples from the remaining approximately 400 patients were not sequenced. This was largely accounted for by unsuitability due to extensive necrosis, secondary to neoadjuvant radiotherapy or chemotherapy, or being placed in formalin. The number of informative genomes produced was reduced further by a PCR amplification step. We showed that this loss of genomic data could be mitigated by sequencing whole genomes from needle core biopsies. Storage of resection specimens at 4 °C for up to 96 h overcame the challenge of freezing tissue out of hours including weekends. Removing access to formalin increased compliance to these storage arrangements. With over 70 different sarcoma subtypes described, WGS was a useful tool for refining diagnoses and identifying novel alterations. Genomes from 350 of the cohort of 597 patients were analysed in this study. Overall, diagnoses were modified for 3% of patients following review of the WGS findings. Continued refinement of the variant‐calling bioinformatic pipelines is required as not all alterations were identified when validated against histology and standard of care diagnostic tests. Further research is necessary to evaluate the impact of germline mutations in patients with sarcoma, and sarcomas with evidence of hypermutation. Despite 50% of the WGS exhibiting domain 1 alterations, the number of patients with sarcoma who were eligible for clinical trials remains small, highlighting the need to revaluate clinical trial design. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results